About Itropine

Myopia, or nearsightedness, has skyrocketed in prevalence world-wide. Controlling the myopia epidemic is at the forefront of eye care as myopia is the leading cause of vision impairment in children.

Upwards of 25 million children are diagnosed with myopia in the United States, and it is far more ubiquitous in East Asia. More than 10% of these patients are likely to get pathological myopia, which can cause permanent vision loss. These numbers grow as the genetic factors become stronger and environmental factors become more prominent.

Implementation of myopia control in clinical practice is a step towards making a global impact. Equally important, the benefits are substantial for the individual receiving treatment. In this context Itropine drops are an effective therapy for reducing myopia progression.

First marketed in 2015, over 10 million doses of Itropine have been prescribed for myopia control. In fact, Itropine is the FIRST in the world to provide evidenced-based research with clinical trials. Having this foundation element in medicine builds confidence for physicians and patients.

 

 

Itropine is a topical ophthalmic that plays a significant role in myopia management due to its ability to retard refractive advancement in myopic eyes. Itropine achieves this significant therapeutic benefit in a reliable, preservative free formulation for patients.

The preservative free benefits of Itropine provide an advantageous safety profile because it avoids the possibility of cytotoxic damage that preservatives have on the ocular surface. This helps eliminate symptoms of allergies, irritation, and dryness. In addition, Itropine come in single dose, individual vials for application that is both convenient and avoids cross contamination.

Learn more about prescribing Itropine in your clinical practice on the Physician subpage.
Get more information on using Itropine as a patient on the Patient subpage.